IL2 and renal cell carcinoma: Further, RCC patients treated with HD IL-2 monotherapy exhibited an ORR of 25% (171), however the combination therapy with PD‐1/PD‐L1 blockade did not improve therapeutic outcomes in these patients with an ORR of 24% (170).